难治性肠易激综合征认知行为治疗后的胃肠道症状改善
这项随机对照试验纳入436例罗马III标准肠易激综合征患者,比较标准化认知行为治疗、以家庭为主的认知行为治疗与患者教育。以家庭为主的认知行为治疗在治疗结束后2周和6个月时胃肠道症状改善比例均高于教育组,且疗效不劣于标准化认知行为治疗。
要点
- 以家庭为主的认知行为治疗组治疗结束后2周患者评定症状改善比例为61.0%,教育组为43.5%(P<.05)。
- 消化科医生评定6个月时症状改善比例:以家庭为主认知行为治疗组58.4% vs 教育组44.8%(P=.05)。
- 以家庭为主的认知行为治疗在改善肠易激综合征症状方面至少与标准化认知行为治疗等效。
核心结论
- 在以家庭为主的认知行为治疗与教育的随机对照试验中,以家庭为主的认知行为治疗对肠易激综合征患者产生了显著且持续的胃肠道症状改善。
研究设计与样本
- 前瞻性随机对照试验,于2010年8月23日至2016年10月21日在2个三级中心纳入436例符合罗马III标准的肠易激综合征患者(年龄41.4±14.8岁;80%为女性)。
主要发现
- 治疗结束后2周,以家庭为主认知行为治疗组报告中度至显著胃肠道症状改善的比例为61.0%(患者评定)和55.7%(消化科医生评定),教育组分别为43.5%(患者评定)和40.4%(消化科医生评定)(P<.05)。
- 治疗结束后6个月,消化科医生评定的胃肠道症状改善比例在以家庭为主认知行为治疗组为58.4%,教育组为44.8%(P=.05)。
- 多项对比的正式等效性检验表明,以家庭为主的认知行为治疗在改善肠易激综合征症状方面至少与标准化认知行为治疗等效。
- 基于治疗结束后即刻的客户满意度问卷,患者对认知行为治疗的满意度倾向于高于教育(P<.05)。
- 症状改善与合并用药无显著相关。
关键数值与推荐
- 以家庭为主的认知行为治疗组接受4次以家庭为主、所需治疗师接触最少的认知行为治疗,患者获得涵盖与标准化认知行为治疗相同程序的自学材料。
- 标准化认知行为治疗组接受10次每周1次、每次60分钟的治疗,强调提供脑-肠相互作用信息、症状及其诱因和后果的自我监测、肌肉放松、担忧控制、灵活问题解决及复发预防训练。
- 教育组接受4次肠易激综合征教育,提供支持和关于肠易激综合征及压力、饮食、运动等生活方式因素作用的信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is an urgent need for safe treatments for irritable bowel syndrome (IBS) that relieve treatment-refractory symptoms and their societal and economic burden. Cognitive behavior therapy (CBT) is an effective treatment that has not been broadly adopted into routine clinical practice. We performed a randomized controlled trial to assess clinical responses to home-based CBT compared with clinic-based CBT and patient education. METHODS: We performed a prospective study of 436 patients with IBS, based on Rome III criteria, at 2 tertiary centers from August 23, 2010, through October 21, 2016. Subjects (41.4 ± 14.8 years old; 80% women) were randomly assigned to groups that received the following: standard-CBT (S-CBT, n = 146, comprising 10 weekly, 60-minute sessions that emphasized the provision of information about brain-gut interactions; self-monitoring of symptoms, their triggers, and consequences; muscle relaxation; worry control; flexible problem solving; and relapse prevention training), or 4 sessions of primarily home-based CBT requiring minimal therapist contact (MC-CBT, n = 145), in which patients received home-study materials covering the same procedures as S-CBT), or 4 sessions of IBS education (EDU, n = 145) that provided support and information about IBS and the role of lifestyle factors such as stress, diet, and exercise. The primary outcome was global improvement of IBS symptoms, based on the IBS-version of the Clinical Global Impressions-Improvement Scale. Ratings were performed by patients and board-certified gastroenterologists blinded to treatment allocation. Efficacy data were collected 2 weeks, 3 months, and 6 months after treatment completion. RESULTS: A higher proportion of patients receiving MC-CBT reported moderate to substantial improvement in gastrointestinal symptoms 2 weeks after treatment (61.0% based on ratings by patients and 55.7% based on ratings by gastroenterologists) than those receiving EDU (43.5% based on ratings patients and 40.4% based on ratings by gastroenterologists) (P < .05). Gastrointestinal symptom improvement, rated by gastroenterologists, 6 months after the end of treatment also differed significantly between the MC-CBT (58.4%) and EDU groups (44.8%) (P = .05). Formal equivalence testing applied across multiple contrasts indicated that MC-CBT is at least as effective as S-CBT in improving IBS symptoms. Patients tended to be more satisfied with CBT vs EDU (P < .05) based on immediate posttreatment responses to the Client Satisfaction Questionnaire. Symptom improvement was not significantly related to concomitant use of medications. CONCLUSIONS: In a randomized controlled trial, we found that a primarily home-based version of CBT produced significant and sustained gastrointestinal symptom improvement for patients with IBS compared with education. Clinicaltrials.gov no.: NCT00738920.
引用
- Lackner JM, Jaccard J, Keefer L, et al. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. Gastroenterology. 2018. PMID: 29702118. doi:10.1053/j.gastro.2018.03.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。